In short
A groundbreaking Phase 3 clinical trial is underway to investigate the effectiveness of Zelpultide Alfa, a recombinant human surfactant protein-D, in preventing bronchopulmonary dysplasia (BPD) in high-risk premature infants. This study aims to compare the efficacy of Zelpultide Alfa added to standard care versus standard care plus placebo in reducing the incidence of severe BPD and death in these vulnerable newborns.
At a glance
- Drug Name
- Zelpultide Alfa (AT-100)
- Active Substance
- Recombinant Human Surfactant Protein-D (rhSP-D)
- Trial Phase
- Phase 3
- Target Population
- High-risk preterm neonates (23 0/7 to 27 6/7 weeks gestational age)
- Primary Objective
- Compare efficacy in preventing grade 2 and 3 BPD and death
- Administration Method
- Endotracheopulmonary instillation
- Maximum Daily Dose
- 6 mg/kg
- Maximum Total Dose
- 42 mg/kg over 7 days
- Primary Endpoint
- Incidence of grade 2 or 3 BPD or death at week 36 PMA
What is Zelpultide Alfa?
Zelpultide alfa, also known as AT-100 or Recombinant Human Surfactant Protein-D (rhSP-D), is a new medication being studied to help prevent lung problems in very premature babies. It's a type of protein that's similar to a natural substance found in the lungs.
How Does It Work?
Zelpultide alfa is designed to protect the lungs of premature babies. It's a type of medicine called a surfactant, which helps keep the tiny air sacs in the lungs open and working properly. This is especially important for premature babies because their lungs are not fully developed yet.
Who Is This Treatment For?
This treatment is being studied for very premature babies who are at high risk of developing a serious lung condition called bronchopulmonary dysplasia (BPD). BPD is a chronic lung disease that can occur in premature infants, especially those born between 23 and 28 weeks of pregnancy.
Current Clinical Trial
Zelpultide alfa is currently being tested in a Phase 3 clinical trial. This is an important step in determining if the medication is safe and effective. The study is comparing zelpultide alfa added to standard care versus standard care alone in premature babies.
The main goals of the study are to see if zelpultide alfa can:
- Reduce the number of babies who develop severe BPD or die
- Decrease other breathing problems related to being born prematurely
- Improve long-term brain development
- Reduce the need for medical care and associated costs
Potential Benefits
If successful, zelpultide alfa could help:
- Prevent or reduce the severity of BPD in premature babies
- Reduce the time babies need to spend on breathing machines
- Improve overall health outcomes for premature infants
How Is It Given?
Zelpultide alfa is given directly into the baby's lungs through a breathing tube. It's given along with standard care for premature babies. The maximum daily dose being tested is 6 mg per kilogram of the baby's weight, and the treatment may be given for up to 7 days.
It's important to note that this medication is still being studied and is not yet approved for general use. The ongoing clinical trial will help determine if it's safe and effective for premature babies.